Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02409680 · ClinicalTrials.gov registry record · NA
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
A NA study, sponsored by NICHD Global Network for Women's and Children's Health.
- Completed
- Registry status
- NA
- Development phase
- 11,976
- Enrollment target
NCT02409680: Completed NA study, sponsored by NICHD Global Network for Women's and Children's Health.
NCT02409680 is a NA study that has completed, run by NICHD Global Network for Women's and Children's Health. The registered enrollment target is 11,976 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (754% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02409680, a NA study, has completed, sponsored by NICHD Global Network for Women's and Children's Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 11,976 participants
- Enrollment target
Study Summary
Available data suggest that low dose aspirin may be a safe, widely available and inexpensive intervention that may significantly reduce the risk of preterm birth. However, this possibility needs to be proven in a properly designed randomized controlled trial (RCT) with preterm birth as the primary outcome. Such a clinical trial in a racially, ethnically and geographically diverse population could best be accomplished by the established infrastructure of the Global Network for Women's and Children's Health Research (GN).
Primary Outcome
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous.
Interventions
- DRUG Placebo
- DRUG Low dose aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,976 participants |
| Start Date | 2016-03-23 |
| Est. Completion | 2019-04-11 |
| Phase | NA |
What the finished NCT02409680 record still lists
NCT02409680 is an interventional study that assigns participants to a tested intervention. Its 11,976 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (754% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02409680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02409680 about?
NCT02409680 is a clinical study titled "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)". Available data suggest that low dose aspirin may be a safe, widely available and inexpensive intervention that may significantly reduce the risk of preterm birth. However, this possibility needs to be proven in a properly designed randomized controlled trial (RCT) with preterm birth as the primary o...
What is the current status of trial NCT02409680?
This trial is currently completed. It is a NA study. The enrollment target is 11,976 participants. The study started on 2016-03-23. Estimated completion is 2019-04-11.
What interventions are being tested in trial NCT02409680?
The interventions under investigation include: Placebo (DRUG), Low dose aspirin (DRUG).
Who is sponsoring clinical trial NCT02409680?
This trial is sponsored by NICHD Global Network for Women's and Children's Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02409680's enrollment target sits among peer trials
11,976 14th of 2000 higher than 1,987 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01772771 · 12,000 participants
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- NCT04937868 · 12,000 participants
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
- NCT06059963 · 12,000 participants
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
- NCT06273618 · 12,000 participants · NA
iLookOut Micro-learning to Improve Knowledge Retention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI